Sustained delivery of a HIF-1 antagonist for ocular neovascularization (Q30560557)

19 October 2017

Sustained delivery of a HIF-1 antagonist for ocular neovascularization (English)

1 reference

19 October 2017

1 reference

Ming Yang

0 references

Gregg L Semenza

1 reference

19 October 2017

Justin Hanes

1 reference

19 October 2017

Takeshi Iwase

1 reference

19 October 2017

Jie Fu

1 reference

19 October 2017

Tsunehiko Yoshida

1 reference

19 October 2017

Daisuke Muramatsu

1 reference

19 October 2017

Akiko Miki

1 reference

19 October 2017

Noriyasu Hashida

1 reference

19 October 2017

Lili Lu

1 reference

19 October 2017

Brian Oveson

1 reference

19 October 2017

Raquel Lima e Silva

1 reference

19 October 2017

Christopher Seidel

1 reference

19 October 2017

Sheila Connelly

1 reference

19 October 2017

Jikui Shen

1 reference

19 October 2017

Bing Han

1 reference

19 October 2017

Mingsheng Wu

1 reference

19 October 2017

Peter A Campochiaro

1 reference

19 October 2017

language of work or name

English

0 references

publication date

12 October 2013

1 reference

Journal of Controlled Release

19 October 2017

1 reference

19 October 2017

172

1 reference

19 October 2017

1 reference

19 October 2017

625-633

1 reference

Hydrosilylated porous silicon particles function as an intravitreal drug delivery system for daunorubicin.

19 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Oxidized porous silicon particles covalently grafted with daunorubicin as a sustained intraocular drug delivery system

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Real-time monitoring of sustained drug release using the optical properties of porous silicon photonic crystal particles

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Ranibizumab for neovascular age-related macular degeneration

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Antioxidants reduce cone cell death in a model of retinitis pigmentosa

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

VEGF is major stimulator in model of choroidal neovascularization.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Effects of intraocular ranibizumab and bevacizumab in transgenic mice expressing human vascular endothelial growth factor

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

PEG-PLA Block Copolymer as Potential Drug Carrier: Preparation and Characterization

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Blockade of the Stromal Cell–Derived Factor-1/CXCR4 Axis AttenuatesIn vivoTumor Growth by Inhibiting Angiogenesis in a Vascular Endothelial Growth Factor–Independent Manner

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Increased expression of brain-derived neurotrophic factor preserves retinal function and slows cell death from rhodopsin mutation or oxidative damage.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Angiopoietin-2 plays an important role in retinal angiogenesis

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3871855

The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years

26 November 2018

1 reference

12 December 2020

Prevalence of age-related maculopathy. The Beaver Dam Eye Study

1 reference

12 December 2020

Intravitreal Sustained Release of VEGF Causes Retinal Neovascularization in Rabbits and Breakdown of the Blood– Retinal Barrier in Rabbits and Primates

1 reference

12 December 2020

Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors

1 reference

12 December 2020

In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels

1 reference

12 December 2020

The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization

1 reference

12 December 2020

Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa

1 reference

12 December 2020

The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed Dosing

1 reference

12 December 2020

10.1016/J.JCONREL.2013.10.008

Identifiers

DOI

1 reference

19 October 2017

1 reference

19 October 2017

PubMed publication ID

24126220

1 reference